Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study.

Stenotrophomonas maltophilia cohort study combination therapy monotherapy treatment

Journal

Expert review of anti-infective therapy
ISSN: 1744-8336
Titre abrégé: Expert Rev Anti Infect Ther
Pays: England
ID NLM: 101181284

Informations de publication

Date de publication:
13 May 2024
Historique:
medline: 13 5 2024
pubmed: 13 5 2024
entrez: 13 5 2024
Statut: aheadofprint

Résumé

The aim of this study was to compare the safety and effectiveness of monotherapy versus combination therapy for the treatment of infections caused by This retrospective, multicenter, cohort study included patients treated with either monotherapy or combination therapy for infections caused by A total of 407 patients were included, 330 patients received monotherapy and 77 patients received combination therapy. A total of 21% presented with concomitant bacteremia. After adjusting the differences between the two groups, there were no statistically significant differences between patients who received monotherapy versus combination therapy in clinical cure (55% vs 65%; OR, 0.72; 95% CI, 0.40-1.31) and overall in-hospital mortality (52% vs 49%; OR, 0.84; 95% CI, 0.45-1.57). However, patients who received monotherapy had a lower rate of 30-day mortality (28% vs 32%; OR, 0.45; 95% CI, 0.22-0.90) and acute kidney injury (9% vs 18%; OR, 0.35; 95% CI, 0.16-0.78). Clinical outcomes did not significantly differ in patients who received combination therapy versus monotherapy. More data are needed to validate these findings.

Sections du résumé

BACKGROUND UNASSIGNED
The aim of this study was to compare the safety and effectiveness of monotherapy versus combination therapy for the treatment of infections caused by
METHODS UNASSIGNED
This retrospective, multicenter, cohort study included patients treated with either monotherapy or combination therapy for infections caused by
RESULTS UNASSIGNED
A total of 407 patients were included, 330 patients received monotherapy and 77 patients received combination therapy. A total of 21% presented with concomitant bacteremia. After adjusting the differences between the two groups, there were no statistically significant differences between patients who received monotherapy versus combination therapy in clinical cure (55% vs 65%; OR, 0.72; 95% CI, 0.40-1.31) and overall in-hospital mortality (52% vs 49%; OR, 0.84; 95% CI, 0.45-1.57). However, patients who received monotherapy had a lower rate of 30-day mortality (28% vs 32%; OR, 0.45; 95% CI, 0.22-0.90) and acute kidney injury (9% vs 18%; OR, 0.35; 95% CI, 0.16-0.78).
CONCLUSION UNASSIGNED
Clinical outcomes did not significantly differ in patients who received combination therapy versus monotherapy. More data are needed to validate these findings.

Identifiants

pubmed: 38738566
doi: 10.1080/14787210.2024.2353704
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Auteurs

Thamer A Almangour (TA)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Hussain A Alali (HA)

Clinical Pharmacy Services, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

Zakiyah Alkherb (Z)

Clinical Pharmacy Services, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

Shuroug A Alowais (SA)

Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Pharmaceutical Care Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.

Khalid Bin Saleh (K)

Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Pharmaceutical Care Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.

Sara Almuhisen (S)

Pharmacy services administration, King Fahad Medical City, Riyadh, Saudi Arabia.

Abdullah Almohaizeie (A)

Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.

Renad Alsahli (R)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Shatha Alruwaite (S)

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Fai Alnashmi (F)

Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Pharmaceutical Care Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.

Lolwa Fetyani (L)

Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Pharmaceutical Care Department, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.

Noran Ibrahim Abouobaid (NI)

Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

Alnajla Alghofaily (A)

Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

Khalifa M Binkhamis (KM)

Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

Yazed Saleh Alsowaida (YS)

Department of Clinical Pharmacy, College of Pharmacy, University of Ha'il, Hail, Saudi Arabia.

Classifications MeSH